Mountain Valley MD (CSE: MVMD) Director of Life Sciences Mike Farber joined Steve Darling from Proactive with news the company has received a patent for their Quicksome Technology. This patent approval is the first for MVMD in the Canadian marketplace to pass the formal allowance stage.
Farber telling Proactive the Quicksome liposome technology utilizes an advanced two-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats. Farber also shared with Proactive why therapeutics and not just vaccines will be the way the world needs to deal with pandemics in the future.
